Center for Disease Control
Hepatitis B Fact Sheet |
|
Clinical
Features
- Jaundice, fatigue,
abdominal pain, loss of appetite, intermittent nausea, vomiting
Etiologic
Agent
Incidence
- 140,000-320,000 infections/yr in United States
- 70,000-160,000 symptomatic infections/yr
Sequelae
- Of symptomatic
infections, 8400-19,000 hospitalizations/yr and 140-320 (0.2%) deaths/yr;
- Of all infections,
8,000-32,000 (6%-10%) chronic infections/yr, and 5,000-6,000 deaths/yr
from chronic liver disease including primary liver cancer
Prevalence
- Estimated 1-1.25 million chronically infected Americans
Costs
- Estimated $700 million (1991 dollars)/yr (medical and work loss)
Transmission
- Bloodborne
- Sexual
- Perinatal
Risk
Groups
- Injection drug users
- Sexually active heterosexuals
- Men who have sex with men
- Infants/children of immigrants from disease-endemic areas
- Low socioeconomic level
- Sexual/household contacts of infected persons
- Infants born to infected mothers
- Health care workers
- Hemodialysis patients
Surveillance
- National Notifiable Diseases Surveillance System
- Viral Hepatitis Surveillance Program
- Sentinel Counties Studies
Trends
Incidence increased through 1985 and then declined 55% through
1993 because of wider use of vaccine among adults, modification of high-risk
practices, and possibly a decrease in the number of susceptible persons.
Since 1993, increases observed among the three major risk groups: sexually
active heterosexuals, homosexual men, and injection drug users.
Prevention
- Hepatitis B vaccine available since 1982
- Screening pregnant women and treatment of infants born to infected
women
- Routine vaccination of infants and 11-12 year olds
- Catch-up vaccination of high-risk groups of all ages
- Screening of blood/organ/tissue donors
click
here for printable version